Background illustration for clinical trials search

Paid Clinical Trials Edmond

Discover 573 paid clinical trials in Edmond, Oklahoma. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 573

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for

Locally Advanced Cervical Adenocarcinoma,

Location: Oklahoma City OK, Tulsa OK, Springdale AR,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT07061977

Phase 3, Recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for

Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular,

Location: Oklahoma City OK, Fort Worth TX, Dallas TX,

Sponsor: Children's Oncology Group

Sex: All

Age: 1 - 30

Code: NCT03126916

Phase 3, Recruiting

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

for

Extensive Stage Lung Small Cell Carcinoma,

Location: Oklahoma City OK, Salina KS, Olathe KS,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06769126

Phase 2, Recruiting

Enhancing Smoking Cessation for African American People Everywhere

for

ESCAPE Intervention+NRT, quitSTART Intervention+NRT, CTRL+NRT

Location: Oklahoma City OK

Sponsor: University of Houston

Sex: All

Age: 18+

Code: NCT07024992

Phase 2, Recruiting

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

for

Lung Non-Small Cell Carcinoma

Location: Oklahoma City OK, Olathe KS, Overland Park KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07388524

Phase 3, Recruiting

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

for

Ulcerative Colitis, Crohn's Disease

Location: Oklahoma City OK

Sponsor: Takeda

Sex: All

Age: 2 - 17

Code: NCT06405087

Phase 3, Recruiting

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

for

Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia

Location: Oklahoma City OK, Wellington KS, Winfield KS,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 65+

Code: NCT07321652

Phase 3, Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Oklahoma City OK, Springdale AR, Richardson TX,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07061964

Phase 2, Recruiting

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

for

Core Binding Factor Acute Myeloid Leukemia

Location: Oklahoma City OK, Overland Park KS, Fairway KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT06917911

Phase 2, Recruiting

Empowering Cessation ACS South Region

for

Smoking Cessation

Location: Oklahoma City OK

Sponsor: University of Oklahoma

Sex: All

Age: 18 - 70+

Code: NCT06820034

Phase 2, Phase 3, Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for

Endometrial Adenocarcinoma,

Location: Oklahoma City OK, Richardson TX, Dallas TX, Omaha NE,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05112601

Phase 2, Recruiting

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for

Pancreatic Neoplasm

Location: Oklahoma City OK, Dallas TX, Little Rock AR,

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All

Age: 50 - 70+

Code: NCT04239573

Recruiting

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

for

Diffuse Cutaneous Systemic Sclerosis

Location: Oklahoma City OK, Allen TX, Dallas TX, Aurora CO,

Sponsor: Mediar Therapeutics

Sex: All

Age: 18+

Code: NCT07287670

Phase 2, Recruiting

The Vanguard Study: Testing a New Way to Screen for Cancer

for

Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma,

Location: Oklahoma City OK, Springfield MO, Kansas City MO,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 45 - 70+

Code: NCT06995898

Recruiting

E-Mindfulness Approaches for Living After Breast Cancer

for

Breast Cancer, Depression

Location: Oklahoma City OK, Fort Smith AR, Amarillo TX, Topeka KS,

Sponsor: NRG Oncology

Sex: All

Age: 18 - 50

Code: NCT06748222

Phase 3, Recruiting

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

for

Prostate Cancer (Adenocarcinoma)

Location: Oklahoma City OK, Lawton OK, Dallas TX, Kearney NE,

Sponsor: Canadian Cancer Trials Group

Sex: Male

Age: 18+

Code: NCT06592924

Phase 3, Recruiting

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

for

Recurrent Non-Muscle Invasive Bladder Carcinoma,

Location: Oklahoma City OK, Cheyenne WY, Metairie LA,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07000084

Phase 3, Recruiting

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

for

Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia

Location: Oklahoma City OK, Tulsa OK, Dallas TX, Fort Worth TX,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 1 - 30

Code: NCT04546399

Phase 2, Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

for

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,

Location: Oklahoma City OK, Salina KS, Westwood KS,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06532279

Phase 2, Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

for

Solid Cancer

Location: Oklahoma City OK, Tulsa OK, Fort Worth TX, Houston TX,

Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06161025

Phase 2, Phase 3, Recruiting

Paid Clinical Trials Edmond

Filter results

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Enhancing Smoking Cessation for African American People Everywhere

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Interested in new trials?

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Empowering Cessation ACS South Region

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

The Vanguard Study: Testing a New Way to Screen for Cancer

E-Mindfulness Approaches for Living After Breast Cancer

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer